Disruption of the claustrum-ACC pathway contributes to human mind blanking.

Neurobiol DisJul 4, 2026 (epub)
Clinical ResearchNeurology

Yueyang Cheng, Yixi Zheng, Wei Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This clinical trial investigated the role of the claustrum-ACC pathway in mind blanking (MB) among eight patients with drug-resistant epilepsy undergoing SEEG. Focal stimulation of the left claustrum induced MB in one patient, accompanied by suppression of neural activity in the ACC. The study highlights the critical involvement of this pathway in conscious thought.

Key findings

  • Focal stimulation of the left claustrum induced mind blanking in one of eight patients.
  • Simultaneous recordings showed site-specific suppression of neural activity in the anterior cingulate cortex.
  • Machine learning analysis identified ACC spectral attenuation as a reliable fingerprint of stimulation-induced mind blanking.
  • 1 Hz claustrum-cortical evoked potentials confirmed a robust claustrum-ACC pathway.

Why it matters

Understanding the neural mechanisms underlying mind blanking can enhance insights into conscious experience and cognitive disruptions. This knowledge may inform future therapeutic strategies for conditions associated with altered consciousness.

Source

PubMed · PMID 42401244

Published in Neurobiol Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.